Search
Search Results
-
Advances in CAR-T-cell therapy in T-cell malignancies
Significant advances have been made in chimeric antigen receptor T (CAR-T)-cell therapy for the treatment of recurrent or refractory B-cell...
-
EBV-associated lymphoproliferative disease post-CAR-T cell therapy
Epstein–Barr virus (EBV)-associated lymphoproliferative diseases (EBV-LPDs) are common complications that occur after solid organ transplantation or...
-
Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers
BackgroundChimeric antigen receptor (CAR) T-cell therapy and bispecific T-cell engagers, which redirect T-cells to tumor antigens, have immensely...
-
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy
T cell differentiation is a highly regulated, multi-step process necessary for the progressive establishment of effector functions, immunological...
-
CAR-T cell therapy in AML: recent progress and future perspectives
Despite several small-molecule drugs that have revolutionized the current treatment strategy for acute myeloid leukemia (AML), hematopoietic stem...
-
Hepatitis B virus reactivation associated with CAR T-cell therapy
Patients with hematological malignancies who also have a hepatitis B virus (HBV) infection need to be aware of the potential risk of HBV reactivation...
-
Fueling CARs: metabolic strategies to enhance CAR T-cell therapy
CAR T cells are widely applied for relapsed hematological cancer patients. With six approved cell therapies, for Multiple Myeloma and other B-cell...
-
CAR-T cell therapy: a game-changer in cancer treatment and beyond
In recent years, cancer has become one of the primary causes of mortality, approximately 10 million deaths worldwide each year. The most advanced,...
-
Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy
In recent years, chimeric antigen receptor T-cell therapy (CAR T) has revolutionized the treatment landscape for large B cell lymphoma (LBCL),...
-
Current progress of CAR-T-cell therapy for patients with multiple myeloma
Currently available chimeric antigen receptor (CAR)-engineered T-cell therapies targeting B-cell maturation antigen (BCMA), namely, idecabtagene...
-
Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy
Chimeric antigen receptor (CAR)-T cell therapy is a promising new treatment for cancer that involves genetically modifying a patient’s T-cells to...
-
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
T-cell malignancies are associated with frequent relapse and high morbidity, which is partly due to the lack of effective or targeted treatment...
-
Challenges and strategies associated with CAR-T cell therapy in blood malignancies
Cellular immunotherapy, particularly CAR-T cells, has shown potential in the improvement of outcomes in patients with refractory and recurrent...
-
Transdifferentiation of diffuse large B-cell lymphoma to a poorly differentiated neoplasm following CAR T-cell therapy
Chimeric antigen receptor T-cell (CAR-T) therapy is a recent advancement in precision medicine with promising results for patients with relapsed or...
-
Current status of CAR-T cell therapy for pediatric hematologic malignancies
Acute lymphoblastic leukemia (ALL) is the most common cancer in the pediatric population, and the long-term survival can reach 90%. However,...
-
Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies
Although chimeric antigen receptor T cell immunotherapy has been successfully applied in patients with hematological malignancies, several obstacles...
-
CAR-T Cell Therapy: the Efficacy and Toxicity Balance
Purpose of ReviewChimeric antigen receptor (CAR) T cell therapy is an immunotherapy that has resulted in tremendous progress in the treatment of...
-
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
Persistent Immune Effector Cell Associated Hematotoxicity (ICAHT) is a significant side effect of BCMA CAR T-Cell therapy in patients with relapsed...
-
CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting
Due to the concern of fratricide, clinical development of CAR T cells for the therapy of T cell malignancies lags behind that for B cell...
-
Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape
Chimeric antigen receptor (CAR) T-cell therapy has demonstrated clinical response in treating both hematologic malignancies and solid tumors....
